{"groups":[{"description":"Participants received pembrolizumab, 10 mg/kg, intravenously (IV) once every 2 weeks, and continued to receive study drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years). Participants who stopped study treatment without progression (e.g. completed 2 years) may have been eligible for up to 1 year of retreatment upon subsequently experiencing disease progression.","id":"FG000","title":"Cohort A: Triple Negative Breast Cancer"},{"description":"Participants received pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continued to receive study drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years). Participants who stopped study treatment without progression (e.g. completed 2 years) may have been eligible for up to 1 year of retreatment upon subsequently experiencing disease progression.","id":"FG001","title":"Cohort B: Head & Neck Cancer"},{"description":"Participants received pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continued to receive study drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years). Participants who stopped study treatment without progression (e.g. completed 2 years) may have been eligible for up to 1 year of retreatment upon subsequently experiencing disease progression.","id":"FG002","title":"Cohort C: Urothelial Cancer"},{"description":"Participants received pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continued to receive study drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years). Participants who stopped study treatment without progression (e.g. completed 2 years) may have been eligible for up to 1 year of retreatment upon subsequently experiencing disease progression.","id":"FG003","title":"Cohort D: Gastric Cancer"},{"description":"Participants received pembrolizumab, 200 mg, IV once every 3 weeks, and continued to receive study drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years). Participants who stopped study treatment without progression (e.g. completed 2 years) may have been eligible for up to 1 year of retreatment upon subsequently experiencing disease progression.","id":"FG004","title":"Cohort B2: Head & Neck Cancer Expansion"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"9"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"8"},{"groupId":"FG004","numSubjects":"27"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"6"}],"type":"Excluded Medication"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"3"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"11"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"}],"type":"Sponsor Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"36"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"61"},{"groupId":"FG002","numSubjects":"33"},{"groupId":"FG003","numSubjects":"39"},{"groupId":"FG004","numSubjects":"132"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"60"},{"groupId":"FG002","numSubjects":"33"},{"groupId":"FG003","numSubjects":"39"},{"groupId":"FG004","numSubjects":"132"}],"type":"Treated"},{"achievements":[{"comment":"Completed means two-year treatment completed","groupId":"FG000","numSubjects":"13"},{"comment":"Completed means two-year treatment completed","groupId":"FG001","numSubjects":"13"},{"comment":"Completed means two-year treatment completed","groupId":"FG002","numSubjects":"9"},{"comment":"Completed means two-year treatment completed","groupId":"FG003","numSubjects":"13"},{"comment":"Completed means two-year treatment completed","groupId":"FG004","numSubjects":"38"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"48"},{"groupId":"FG002","numSubjects":"24"},{"groupId":"FG003","numSubjects":"26"},{"groupId":"FG004","numSubjects":"94"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"All allocated participants through end of trial (EOT) analysis cutoff date of 30 June 2020."}